Rapid spontaneous water diuresis after trigger removed
Differential Diagnosis
Hypotonic hyponatremia etiologies
Low effective arterial blood volume
Heart failure ICD-10 I50
Hypervolemic hyponatremia phenotype
Cirrhosis ICD-10 K74
Hypervolemic hyponatremia phenotype
Nephrotic syndrome ICD-10 N04
Hypervolemic hyponatremia phenotype
True hypovolemia
GI losses
Renal losses
Euvolemic water retention
SIADH SNOMED CT concept syndrome of inappropriate secretion of antidiuretic hormone
Pulmonary triggers
CNS triggers
Drug triggers
Malignancy triggers
Secondary adrenal insufficiency ICD-10 E27.3
Cortisol deficiency mediated ADH elevation
Hypothyroidism ICD-10 E03
Severe hypothyroid mediated hyponatremia
Low solute intake
Beer potomania phenotype
Low urine osmolality possible
Malnutrition phenotype
Limited osmole excretion capacity
Excess water intake
Primary polydipsia
Very low urine osmolality pattern
Non-hypotonic hyponatremia mimics
Hypertonic hyponatremia
Hyperglycemia ICD-10 E11.65
Water shift mediated sodium dilution
Isotonic hyponatremia
Pseudohyponatremia
Severe hypertriglyceridemia
Severe hyperproteinemia
Laboratory Tests
Core confirmation set
Sodium disorder panel
Serum osmolality
Hypotonic confirmation threshold less than 275 mOsm/kg
Glucose
Translocational hyponatremia screen
BUN and creatinine
Kidney function context
Potassium
ODS risk modifier when low
Magnesium
Seizure threshold modifier
Phosphate
Refeeding risk context
Urine studies
Urine osmolality
Less than 100 mOsm/kg consistent with excess water intake or low solute intake
Greater than 100 mOsm/kg consistent with ADH activity
Urine sodium
Less than 30 mmol/L consistent with low effective arterial blood volume
Greater than 30 mmol/L consistent with SIADH or renal salt loss
Urine potassium
Electrolyte-free water clearance estimation support
Endocrine and secondary causes
Adrenal axis
Serum cortisol
If low or indeterminate, ACTH stimulation pathway
ACTH
Primary versus secondary pattern support
Thyroid axis
TSH
Severe hypothyroid screen
Free T4
Severity confirmation
Monitoring for therapy
Frequent reassessment labs
Serum sodium serial checks
Every 1 hour to 2 hours during active correction
Serum potassium serial checks
Potassium repletion effect on sodium rise
Serum osmolality serial checks
Overcorrection risk context
Diagnostic Tests
Scoring Systems
Symptom severity classification
Severe symptoms
Seizure
Coma
Cardiorespiratory distress
Deep somnolence
Vomiting
Moderate symptoms
Confusion
Headache
Nausea without vomiting
Mild or absent symptoms
Gait instability
Subtle cognitive slowing
ODS risk stratification
Very high risk features
Serum sodium 105 mmol/L or less
Alcohol use disorder
Malnutrition
Advanced liver disease
Hypokalemia
High-risk correction thresholds
Maximum rise 8 mmol/L in 24 hours
Maximum rise 16 mmol/L in 48 hours
MRI
ODS evaluation
Indications
New dysarthria after correction
New dysphagia after correction
New spasticity after correction
New altered mentation after correction
Timing caveat
MRI may be normal early
Delayed radiographic changes possible
Preferred sequences
Diffusion-weighted imaging
T2 and FLAIR
CT
Alternative intracranial process evaluation
Indications
Focal neurologic deficit
Trauma history
Concern for hemorrhage
Limitation
Cerebral edema may be absent despite severe symptoms
Ultrasound
Volume status adjunct
IVC assessment
Collapsible IVC supporting hypovolemia phenotype
Plethoric IVC supporting hypervolemia phenotype
Lung ultrasound
B-lines supporting pulmonary edema phenotype
Cardiac POCUS
Reduced EF supporting heart failure phenotype
Disposition
Level of care
ICU criteria
Severe symptoms
Seizure
Coma
Respiratory failure
Hypertonic saline infusion requirement
Continuous 3% therapy
Repeated bolus requirement
Serum sodium less than 120 mmol/L with neurologic symptoms
Serum sodium less than 110 mmol/L
Overcorrection event
Desmopressin rescue
Dextrose 5% water re-lowering
Stepdown criteria
Stable after initial bolus response
Sodium rise within target
Symptoms improved
Serial sodium monitoring capability
Every 4 hours to 6 hours after stabilization
Ward criteria
Mild symptoms only
Stable vitals
Reliable monitoring
Clear reversible cause
Thiazide stopped
Hypotonic fluids stopped
Transfer and consultation
Specialty consultation triggers
Nephrology
Sodium less than 120 mmol/L with unclear etiology
Refractory hyponatremia
Overcorrection management
Endocrinology
Suspected adrenal insufficiency
Suspected severe hypothyroidism
Neurocritical care
Seizure refractory
Herniation concern
Suspected ODS
Treatment
Hypertonic saline for severe symptoms
3% sodium chloride bolus strategy
Indications
Seizure
Bolus-first approach
Coma
Bolus-first approach
Severe neurologic symptoms
Deep somnolence
Cardiorespiratory distress
Dosing options by guideline set
US Expert Panel style
3% sodium chloride 100 mL IV over 10 minutes
Repeat up to 2 additional boluses for persistent severe symptoms
Expected rise 2 mmol/L to 3 mmol/L per 100 mL bolus
Target rise 4 mmol/L to 6 mmol/L in first hour for seizures or coma
European guideline style
3% sodium chloride 150 mL IV over 20 minutes
Repeat second bolus if severe symptoms persist
Target rise about 5 mmol/L early
Monitoring during bolus therapy
Serum sodium after each bolus
If rise meets target, pause hypertonic therapy
Neurologic symptom response after each bolus
If seizures stop, shift to controlled correction limits
Continuous 3% sodium chloride infusion option
Indications
Persistent symptoms after bolus strategy
Need for controlled gradual correction after initial target reached
Infusion approach
Initial rate 0.5 mL/kg/hour to 2 mL/kg/hour
Titration based on sodium trend
Line considerations
Peripheral administration acceptable for bolus dosing in many ED pathways
Local institutional policy compliance
Etiology-directed therapy
Hypovolemic hyponatremia
Isotonic saline strategy
0.9% sodium chloride infusion
Goal of restoring effective arterial volume
Anticipate brisk water diuresis as overcorrection trigger
Thiazide-associated
Thiazide discontinuation
Potassium repletion
Controlled correction limits
SIADH
Trigger removal
Offending medication stop
Pulmonary infection treatment
CNS trigger treatment
Fluid restriction
Typical range 800 mL/day to 1200 mL/day
Effectiveness limited when urine osmolality high
Increased solute strategy
Oral urea option when available
Improves free water excretion
Salt tablets with loop diuretic option
Loop diuretic reduces medullary gradient
Vaptans
Avoid routine use in acute severe symptomatic hyponatremia
Overcorrection risk
Hypervolemic hyponatremia
Fluid restriction
Heart failure phenotype
Cirrhosis phenotype
Loop diuretic
Congestion relief
Free water excretion support
Overcorrection prevention and rescue
Correction limit enforcement
Maximum rise 10 mmol/L in first 24 hours
ODS risk statement
Maximum rise 8 mmol/L per 24 hours after first day
ODS risk statement
High ODS risk maximum rise 8 mmol/L in 24 hours
Conservative target when risk factors present
Desmopressin strategy
Indications
Rapid sodium rise trajectory
Increasing urine output
Falling urine osmolality
High ODS risk with chronic or unknown duration
Dosing
Desmopressin 2 mcg IV
Repeat every 6 hours to 8 hours as needed
Clamp strategy option
Desmopressin 2 mcg intranasal
Alternate route when IV unavailable
Evidence notes
Desmopressin effective in preventing or reversing inadvertent overcorrection in observational data
Re-lowering therapy
Indications
Correction beyond target thresholds
Overcorrection definition rise greater than 10 mmol/L in first 24 hours
Overcorrection definition rise greater than 8 mmol/L per 24 hours thereafter
Dextrose 5% water
Infusion titrated to lower sodium toward safe range
Frequent sodium checks every 1 hour to 2 hours
Desmopressin plus dextrose 5% water combination
Stops water diuresis
Allows controlled re-lowering
Adjuncts
Seizure management
Benzodiazepine
Lorazepam 2 mg IV
Repeat dosing per status epilepticus pathway
Hypertonic saline as definitive therapy for hyponatremic seizures
Seizure cessation target with 4 mmol/L to 6 mmol/L sodium rise
Potassium repletion
Hypokalemia correction
Low potassium increases ODS risk
Potassium replacement can raise serum sodium
Class and guideline framing
Hypertonic saline bolus for severe symptomatic hyponatremia
Class I recommendation based on consensus pathways
ACEP Level C alignment with expert consensus summaries
Special Populations
Pregnancy
Pregnancy considerations
Etiology differentials
Hyperemesis gravidarum with volume depletion
Oxytocin-associated water retention
Preeclampsia with fluid shifts
Treatment principles
Severe symptoms treated same as nonpregnant
Hypertonic saline bolus for seizures or coma
Correction limits maintained
ODS prevention threshold logic
Consultation triggers
Obstetrics involvement for maternal fetal monitoring
ICU involvement for severe symptoms
Geriatric
Older adult considerations
High-risk drivers
Thiazide use prevalence
SSRI use prevalence
Reduced renal free water clearance
Fall and fracture risk
Gait instability association with chronic hyponatremia
Correction safety
Conservative correction target when duration unclear
Early desmopressin use consideration when high ODS risk
Pediatrics
Pediatric considerations
Dosing approach
3% sodium chloride 2 mL/kg IV over 10 minutes for severe symptoms
Repeat bolus if persistent seizures
Max bolus volume institutional cap consideration
Etiology pattern
Gastroenteritis with hypovolemia
CNS infection related SIADH
Monitoring
Sodium checks every 1 hour to 2 hours during active correction
Strict correction limits for chronic or unknown duration
Background
Epidemiology
Epidemiology summary
Common inpatient electrolyte disorder
Higher prevalence in hospitalized and ICU cohorts
Severe hyponatremia definition patterns
Serum sodium less than 120 mmol/L common severe threshold
Symptom risk increases below 120 mmol/L
Mortality association
Severe symptomatic hyponatremia associated with high inpatient mortality in observational cohorts
Pathophysiology
Osmotic physiology
Hypotonic plasma drives water into brain
Cerebral edema mechanism
Seizure mechanism
Brain adaptation over 48 hours
Osmolyte loss reduces edema
Sets stage for ODS with rapid correction
ODS mechanism
Rapid extracellular tonicity rise
Oligodendrocyte injury
Demyelination risk
Risk increased with chronicity and low baseline sodium
Sodium 105 mmol/L or less as high risk marker
Therapeutic Considerations
Hypertonic saline rationale
Small controlled sodium rise reverses cerebral edema risk
Early target rise 4 mmol/L to 6 mmol/L for seizures or coma
Bolus strategy rationale
Faster symptom relief
Lower total hypertonic exposure
Guideline-supported bolus dosing approaches
Correction limit rationale
ODS prevention
Overcorrection thresholds in endocrine emergency guidance
Desmopressin rationale
Water diuresis control
Prevents unintended rapid correction
Observational evidence supports effectiveness
Patient Discharge Instructions
copy discharge instructions
Discharge instructions
ED discharge uncommon for severe hyponatremia
Admission expectation for sodium less than 125 mmol/L with symptoms
Fluid guidance
Follow clinician-specific fluid restriction plan if SIADH suspected
Avoid excess free water intake
Medication guidance
Stop offending medication only if instructed
Bring medication list to follow-up
Follow-up plan
Repeat serum sodium within 24 hours to 72 hours if discharged
Primary care or nephrology follow-up as arranged
Return to ED now
Confusion
Severe headache
Vomiting
Seizure
Fainting
Worsening weakness
Shortness of breath
Chest pain
References
Clinical guidelines and society statements
Guideline sources
Society for Endocrinology emergency guidance for severe symptomatic hyponatraemia 2022
European Society of Endocrinology clinical guideline for hyponatraemia 2014
Verbalis JG et al diagnosis evaluation and treatment of hyponatremia 2013
ACEP Critical Care section article resuscitationist approach to severe hyponatremia 2022
Evidence-based sources
Evidence sources
Rondon-Berrios H et al hypertonic saline for hyponatremia review including guideline bolus dosing table
Lawless SJ et al management of acute and chronic hyponatraemia review 2022
Perianayagam A et al desmopressin preventing and reversing overcorrection 2008
Pakchotanon K et al proactive versus reactive desmopressin strategies study 2024
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.